This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Skin Disease, Burns and Wound Care



March 2019

Baricitinib for moderate to severe atopic dermatitis

Baricitinib acts by selectively and reversibly blocking the janus-associated kinase (JAK) enzymes that mediate the pathways involved in the inflammatory process in AD and other inflammatory diseases. Baricitinib is taken orally and is currently licensed for the treatment of moderate to severe active rheumatoid arthritis in adult patients that have not responded well to other therapies. If licensed, baricitinib will offer an additional treatment option for adults with moderate to severe AD.


June 2018

Oleogel-S10 for Inherited Epidermolysis Bullosa

Oleogel-S10 is a topical gel and is being developed as a prescription medicine as for EB, for which there are limited treatment options. Oleogel-S10 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and become mature epithelial skin cells, resulting in rapid wound healing. If licensed, oleogel-S10 will offer a treatment option for wound care in patients with EB who currently have limited therapies available.


May 2018

Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis

Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.


March 2018

Rituximab for Pemphigus Vulgaris

Corticosteriods (anti-inflammatory medicines) are usually used for the treatment of PV. Most people will need to take corticosteroids in addition to another medication to help improve the effectiveness and minimise the doses and side effects of corticosteroids. Rituximab is currently being investigated as a treatment option for PV. Rituximab binds specifically to a protein called CD20 located on pre-B and mature B lymphocytes inducing death of these cells. If licensed, rituximab may offer an additional treatment option for patients with PV after failure of systemic steroids and steroid sparing agents to control the disease.


November 2017

Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking an important molecule in inflammation from a process which allows the body’s immune cells (specifically T-cells) to activate other immune cells and release substances which cause inflammation (cytokines).


November 2017

Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin.


October 2017

Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

  The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to …


April 2017

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Certolizumab pegol is an anti-TNF (anti-tumour necrosis factor) drug. It works by blocking the action of TNF protein and which reduces inflammation. It is currently licensed for the treatment of several chronic inflammatory conditions, including Crohn’s Disease, rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. If licensed for chronic plaque psoriasis in adults it will offer …


January 2017

Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light

Afamelanotide is a new drug to treat generalised vitiligo. Vitiligo is a long-term condition where white patches develop on the skin, because of a lack of pigment in the skin. This condition may cause significant psychological distress. Afamelanotide is administered as an implant once every 28 days with NB-UVB light therapy administered 2-3 times per …


September 2016

Cryopreserved human placental tissue (Stravix) for wound repair

Cryopreserved human placental tissue is a new treatment to aid the healing of wounds that may reduce inflammation and scarring. Skin damage through cuts, burns or surgery are a source of discomfort, inflammation and scarring, and can also lead to infections. Cryopreserved human placental tissue includes molecules and materials expected to aid wound healing as …

Get Alerts